TIDMAGL
RNS Number : 2625L
Angle PLC
30 September 2016
For immediate release 30 September 2016
ANGLE plc
("ANGLE" or "the Company")
RESEARCH DEMONSTRATES POTENTIAL USE OF PARSORTIX IN ASSESSING
CHEMOTHERAPY RESISTANCE
Fourth peer-reviewed publication - highlights key Parsortix
advantages
University Medical Centre Hamburg-Eppendorf (UKE) details
research results in the prestigious journal, Clinical Chemistry
ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech
company, today announces that University Medical Centre
Hamburg-Eppendorf (UKE) has published new research detailing the
use of ANGLE's Parsortix(TM) system in the prestigious
peer-reviewed journal Clinical Chemistry. The paper is entitled
"Accession of Tumor Heterogeneity by Multiplex Transcriptome
Profiling of Single Circulating Tumor Cells" (1) .
The UKE cancer research team lead by Professor Klaus Pantel is a
world-leading authority on the emerging field of liquid biopsy and,
in 2015 alone, published 17 scientific papers in high ranking
journals on different aspects of the application of liquid biopsy
in cancer care.
UKE compared the use of Parsortix with a leading antibody-based
system, in parallel, using the same samples from both prostate and
breast cancer patients. The Parsortix system allowed better
downstream profiling of chemokines, as a result of substantially
higher expression levels on the Parsortix harvested circulating
tumour cells (CTCs).
Chemokines are proteins involved in the signalling between
immune cells and cancer cells that are associated with the
formation of metastasis and chemotherapy resistance. Therefore an
understanding of the chemokine profile may play a key role in
selection of drugs that will be effective for an individual
patient.
The success of the Parsortix system in this application
underpins its broader potential as a highly-effective cell capture
and harvest system based on a combination of size and
deformability. Unlike other commercially available systems,
Parsortix is epitope-independent (not based on antibodies) so
captures viable and undamaged CTCs, including the mesenchymal CTCs
that are missed by other systems. Alternative ctDNA techniques
cannot be used as the required analysis is of RNA.
The RNA analysis of cancer cells offers the opportunity to
stratify patients into phenotypical subgroups according to their
expression profiles, providing an important framework for
therapeutic decisions, including determining which drugs will be
effective for which patient, based on a simple blood test.
Therefore, UKE's work demonstrates further utility of the Parsortix
system and specifically the potential to identify patient
responders in pharmaceutical cancer drug trials and its potential
for use as a companion diagnostic in clinical practice(2) .
Prof. Klaus Pantel, Chairman, Department of Tumour Biology at
UKE's Centre of Experimental Medicine, commented:
"We are excited about the new workflows utilising Parsortix to
study multi marker profiles of single CTCs by low cost qPCR(3)
approaches. The high expression levels of chemokines achieved with
Parsortix offers the potential for its use in therapy selection for
patients and we will be progressing further studies to determine
specific applications."
ANGLE's Founder and Chief Executive, Andrew Newland, added:
"This fourth peer-reviewed publication in a key scientific
journal adds to the growing body of published evidence of
Parsortix's superior performance as a liquid biopsy. The
incorporation of Parsortix in protocols for therapy selection has
the potential to meet a key need in personalised medicine. By
facilitating the determination of which drugs will benefit
individual patients and which will have little clinical benefit yet
cause significant side effects, such protocols will also help
reduce the burden on expensive healthcare resources."
1. The publication is available for download at
http://www.angleplc.com/the-parsortix-system/download-files/
2. The work undertaken developed and utilised low cost staining,
micro-manipulation and qPCR techniques to enable multiplex RNA
profiling. The techniques developed provide wide gene expression
information without the need for high cost next generation
sequencing and consequently may be amenable to widespread adoption
in the future as qPCR systems are already widely available in
hospital laboratories.
3. Quantitative PCR - a rapid diagnostic detection technology
used to identify very small quantities of a specific RNA/DNA
sequence in a sample.
For further information:
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys (Nominated adviser)
Russell Kerr, Oliver Baxendale
(Sales) 020 7397 8900
FTI Consulting
Simon Conway, Mo Noonan,
Stephanie Cuthbert 020 3727 1000
Kimberly Ha (US) 001 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
This announcement contains inside information.
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, China and
Australia and three extensive families of patents are being
progressed worldwide. The system is based on a microfluidic device
that captures live cells based on a combination of their size and
compressibility. Parsortix has a CE Mark for Europe and FDA
authorisation is in process for the United States.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The Parsortix
system is designed to be compatible with existing major medtech
analytical platforms and to act as a companion diagnostic for major
pharma in helping to identify patients that will benefit from a
particular drug and then monitoring the drug's effectiveness.
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAKNNADXKEFF
(END) Dow Jones Newswires
September 30, 2016 02:00 ET (06:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2024 to May 2024
Angle (LSE:AGL)
Historical Stock Chart
From May 2023 to May 2024